PROM1 and acute lymphoblastic leukemia: To test the efficacy of the bispecific CAR-iNKT cells against primary blast cells, we used CRISPRKMT2A-AFF1 ALL cells (supplemental Figure 1A,C), in which CD133 was expressed by ∼65% of the CD19+ blasts (Figure 3A).